Literature DB >> 16304180

Analysis of the contribution of individual substituents in 4,6-aminoglycoside-ribosome interaction.

Sven N Hobbie1, Peter Pfister, Christian Brüll, Eric Westhof, Erik C Böttger.   

Abstract

The 4,6-disubstituted 2-deoxystreptamines interfere with protein biosynthesis by specifically targeting the ribosomal A site. These drugs show subtle variations in the chemical groups of rings I, II, and III. In the present study we used site-directed mutagenesis to generate mutant strains of Mycobacterium smegmatis mc(2)155 SMR5 DeltarrnB with mutations in its single rRNA allele, rrnA. This genetic procedure gives rise to strains carrying homogeneous populations of mutant ribosomes and was used to study the contribution of individual chemical substituents to the binding of 4,6-disubstituted aminoglycosides. X-ray crystal structures of geneticin and tobramycin complexed to oligonucleotides containing the minimal bacterial ribosomal A site were used for interpretation of MICs determined for a panel of 4,6-aminoglycosides, including tobramycin, kanamycin A, kanamycin B, amikacin, gentamicin, and geneticin. Surprisingly, the considerable differences present within ring III did not seem to alter the interaction of the drug with the ribosome, as determined by site-directed mutagenesis of the A site. In contrast, subtle variations in ring I significantly influenced binding: (i) a 4'-hydroxyl moiety participates in the proper drug target interaction; and (ii) a 2'-amino group contributes an additional positive charge to ring I, making the drug less susceptible to any kind of sequence alteration within the decoding site, most notably, to conformational changes induced by transversion of U1495 to 1495A. The 4-amino-2-hydroxyl-1-oxobutyl extension at position 1 of ring II of amikacin provides an additional anchor and renders amikacin less dependent on the structural conformation of nucleotide U1406 compared to the dependencies of other kanamycins. Overall, the set of interactions forming the complex between drug substituents and nucleotides of the A site constitutes a network in which the interactions can partly compensate for each other when they are disrupted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304180      PMCID: PMC1315939          DOI: 10.1128/AAC.49.12.5112-5118.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance.

Authors:  L P Kotra; J Haddad; S Mobashery
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 2.  Aminoglycosides: activity and resistance.

Authors:  M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Misreading of RNA codewords induced by aminoglycoside antibiotics.

Authors:  J Davies; L Gorini; B D Davis
Journal:  Mol Pharmacol       Date:  1965-07       Impact factor: 4.436

4.  Role of 16S rRNA Helix 44 in Ribosomal Resistance to Hygromycin B.

Authors:  P Pfister; M Risch; D E Brodersen; E C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Aminoglycoside resistance with homogeneous and heterogeneous populations of antibiotic-resistant ribosomes.

Authors:  M I Recht; J D Puglisi
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Crystal structure of geneticin bound to a bacterial 16S ribosomal RNA A site oligonucleotide.

Authors:  Quentin Vicens; Eric Westhof
Journal:  J Mol Biol       Date:  2003-02-28       Impact factor: 5.469

7.  Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site.

Authors:  Q Vicens; E Westhof
Journal:  Structure       Date:  2001-08       Impact factor: 5.006

8.  Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding a site.

Authors:  Quentin Vicens; Eric Westhof
Journal:  Chem Biol       Date:  2002-06

9.  The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059.

Authors:  Peter Pfister; Simon Jenni; Jacob Poehlsgaard; Ashley Thomas; Stephen Douthwaite; Nenad Ban; Erik C Böttger
Journal:  J Mol Biol       Date:  2004-10-01       Impact factor: 5.469

10.  The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures.

Authors:  Peter Pfister; Sven Hobbie; Quentin Vicens; Erik C Böttger; Eric Westhof
Journal:  Chembiochem       Date:  2003-10-06       Impact factor: 3.164

View more
  26 in total

1.  Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.

Authors:  Katherine S Long; Christian Munck; Theis M B Andersen; Maria A Schaub; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

2.  Mutant A1555G mitochondrial 12S rRNA and aminoglycoside susceptibility.

Authors:  Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2010-07       Impact factor: 5.191

3.  Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis.

Authors:  Subramanian Akshay; Mihai Bertea; Sven N Hobbie; Björn Oettinghaus; Dimitri Shcherbakov; Erik C Böttger; Rashid Akbergenov
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

4.  Antimicrobial Activity, AME Resistance, and A-Site Binding Studies of Anthraquinone-Neomycin Conjugates.

Authors:  Natalya N Degtyareva; Changjun Gong; Sandra Story; Nathanael S Levinson; Adegboyega K Oyelere; Keith D Green; Sylvie Garneau-Tsodikova; Dev P Arya
Journal:  ACS Infect Dis       Date:  2017-02-17       Impact factor: 5.084

5.  Tobramycin Variants with Enhanced Ribosome-Targeting Activity.

Authors:  Marina Y Fosso; Hongkun Zhu; Keith D Green; Sylvie Garneau-Tsodikova; Kurt Fredrick
Journal:  Chembiochem       Date:  2015-06-17       Impact factor: 3.164

Review 6.  SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models.

Authors:  Richard A Gatti
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

7.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

8.  Positional and neighboring base pair effects on the thermodynamic stability of RNA single mismatches.

Authors:  Amber R Davis; Brent M Znosko
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

9.  Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria.

Authors:  Bettina Schulthess; Daniel Schäfle; Nicole Kälin; Tamara Widmer; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

10.  Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity.

Authors:  Hua Fan-Minogue; David M Bedwell
Journal:  RNA       Date:  2007-11-14       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.